Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2550]

Right program could turn immune cells into cancer killers

Right program could turn immune cells into cancer killers

ESMO 2021: Immune checkpoint inhibitor atezolizumab as a potential game-changer in the treatment of early-stage NSCLC

ESMO 2021: Immune checkpoint inhibitor atezolizumab as a potential game-changer in the treatment of early-stage...

FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations

FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20...

ESMO 21: Patients and non-oncology doctors struggle to keep up with the pace of change in oncology, research shows

ESMO 21: Patients and non-oncology doctors struggle to keep up with the pace of change in oncology, research shows

White blood cells that can help destroy malignant tumours

White blood cells that can help destroy malignant tumours

Classifying EGFR mutations by structure and function offers better way to match non-small cell lung cancer patients to treatments

Classifying EGFR mutations by structure and function offers better way to match non-small cell lung cancer...

How a plant virus could protect and save your lungs from metastatic cancer

How a plant virus could protect and save your lungs from metastatic cancer

Long-term benefit of SABR for operable early-stage NSCLC shown in new study

Long-term benefit of SABR for operable early-stage NSCLC shown in new study

WCLC 2021: UK lung cancer trial shows screening at-risk groups lowers mortality rates

WCLC 2021: UK lung cancer trial shows screening at-risk groups lowers mortality rates

WCLC 2021: Durvalumab and tremelimumab with chemo improved PFS and OS in 1st-line stage IV NSCLC vs chemo

WCLC 2021: Durvalumab and tremelimumab with chemo improved PFS and OS in 1st-line stage IV NSCLC vs chemo

More from ecancer